drugset / Trial / NCT06227026
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Phase 1
Recruiting
10 enrolled
University of Utah
Huntsman Cancer Institute/ University of Utah · collabLentigen Technology, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, non-randomized, phase 1 study of anti-CD19 CAR-T cells against relapsed CD19 positive NHL, CLL and ALL based in a lymphodepletion regimen (fludarabine and cyclophosphamide) and using a CellReGen-based process for manufacturing CAR-T cells. This study will utilize a staggered enrollment design with a safety observation period.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2026-07
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 CAR-T cells | Cell therapy | — | — |